David R. Gandara, MD

Closing out his discussion on CGP, David Gandara, MD, looks toward future opportunities for CGP in screening patients before or after surgery.

Considering the value of comprehensive genomic profiling, David Gandara, MD, highlights the importance of supporting access to testing.

A brief discussion on the value of commercially available comprehensive genomic profiling over homegrown testing.

David Gandara, MD, explains how the scope of comprehensive genomic profiling has shifted from a select few patients to the majority.

A review of how comprehensive genomic profiling can better inform treatment planning and alleviate health care economic burden.

Expert perspective on clinical and personal improvements in cancer care made available by appropriate use of comprehensive genomic profiling.

David Gandara, MD, focuses on the differences between liquid biopsy and tissue-based CGP, suggesting a role for both in the current treatment landscape.

A clinical expert shared insight on the evolution of comprehensive genomic profiling and how it has impacted cancer care.